A Reliable Research Partner in Life Science and Medicine

Recombinant Mouse IL-17A Protein (His Tag)

Catalog Number: PKSM041054

Note: Centrifuge before opening to ensure complete recovery of vial contents.

\mathbf{r}							
H)	es	C	m	n	т	ſΠ	ï

Species Mouse

Source HEK293 Cells-derived Mouse IL-17A protein Thr22-Ala158, with an C-terminal His

Calculated MW 16.2 kDa
Observed MW 17-26 kDa
Accession Q62386

Bio-activity Measured by its ability to induce IL-6 secretion by NIH- 3T3 mouse embryonic

fibroblast cells. The ED_{50} for this effect is 0.25-1. 25 ng/ml.

Properties

Purity > 95 % as determined by reducing SDS-PAGE.

Endotoxin < 0.01 EU per µg of the protein as determined by the LAL method.

Storage Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80

°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of

reconstituted samples are stable at < -20°C for 3 months.

Shipping This product is provided as lyophilized powder which is shipped with ice packs.

Formulation Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.


Normally 5% - 8% trehalose, mannitol and 0.01% Tween 80 are added as protectants

before lyophilization.

Please refer to the specific buffer information in the printed manual.

Reconstitution Please refer to the printed manual for detailed information.

Data



> 95 % as determined by reducing SDS-PAGE.

Background

Elabscience®

Elabscience Biotechnology Co., Ltd.

A Reliable Research Partner in Life Science and Medicine

Interleukin-17 is a potent pro-inflammatory cytokine produced by activated memory T cells. There are at least six members of the IL-17 family in humans and in mice. Mature mouse IL-17A shares 61% and 89% amino acid sequence identity with human and rat IL-17A, respectively. As IL-17 shares properties with IL-1 and TNF-alpha, it may induce joint inflammation and bone and cartilage destruction. This cytokine is found in synovial fluids of patients with rheumatoid arthritis, and produced by rheumatoid arthritis synovium. It increases IL-6 production, induces collagen degradation and decreases collagen synthesis by synovium and cartilage and proteoglycan synthesis in cartilage. IL-17 is also able to increase bone destruction and reduce its formation. Blocking of interleukin-17 with specific inhibitors provides a protective inhibition of cartilage and bone degradation.